1. PH-0053 NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in advanced cancers: phase I trial. (August 2021) Authors: Vivar, O.; Shen, C.; Frakes, J.; Niu, J.; Rosenberg, A.; Weiss, J.; Caudell, J.; Jameson, K.; Said, P.; Seiwert, T. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PH-0159: NANORAY-103: Phase I/II trial of NBTXR3 activated by SBRT in patients with HCC and liver metastases. (November 2020) Authors: De Baère, T.; Pracht, M.; Rolland, Y.; Durand-Labrunie, J.; Nguyen, F.; Bronowicki, J.; Vendrely, V.; Cunha, A. Sa; Croisé-Laurent, V.; Rio, E.; Le Sourd, S.; Said, P.; Gustin, P.; Perret, C.; Peiffert, D.; Deutsch, E.; Chajon, E. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗